Published in Cancer Manag Res on November 23, 2012
Preconditioning thermal therapy: flipping the switch on IL-6 for anti-tumour immunity. Int J Hyperthermia (2013) 0.80
Peritonectomy HIPEC-contemporary results, indications. Chin J Cancer Res (2013) 0.78
Targeted delivery of platinum-taxane combination therapy in ovarian cancer. J Control Release (2015) 0.77
Nausea as a sentinel symptom for cytotoxic chemotherapy effects on the gut-brain axis among women receiving treatment for recurrent ovarian cancer: an exploratory analysis. Support Care Cancer (2016) 0.77
Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study. Br J Cancer (2014) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 13.63
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med (1996) 11.72
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol (2003) 8.31
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med (1996) 5.56
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol (2006) 4.92
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol (2006) 4.33
Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol (2004) 4.15
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst (2003) 3.77
Ovarian carcinoma diagnosis. Cancer (2000) 3.12
Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res (1980) 2.48
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep (1978) 2.42
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol (2011) 2.35
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol (2008) 2.25
A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol (2006) 1.96
Treatment goals in ovarian cancer. Int J Gynecol Cancer (2005) 1.75
A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol (2006) 1.69
Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol (2006) 1.67
Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg (2007) 1.66
Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev (2011) 1.56
Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol (2009) 1.34
Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev (2001) 1.33
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev (2011) 1.30
Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. J Clin Oncol (1995) 1.18
Establishing evidence for change in ovarian cancer surgery--proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis. Gynecol Oncol (2009) 1.10
Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer (2004) 1.04
Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol (2004) 1.02
Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim analysis of a phase II study. Ann Surg Oncol (2009) 0.99
Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperthermia (2007) 0.99
A randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer. Jpn J Clin Oncol (2010) 0.98
Treatment of peritoneal carcinomatosis with intent to cure. J Surg Oncol (2000) 0.92
Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. Eur J Surg Oncol (2010) 0.91
Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol (2007) 0.91
HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome. Gynecol Oncol (2011) 0.90
Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg (2004) 0.87
Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer. J Surg Oncol (2010) 0.87
Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms. Am J Surg (2011) 0.86
Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer (2005) 0.85
Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data. Expert Rev Anticancer Ther (2012) 0.84
Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. Ann Oncol (2007) 0.83
Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. Ann Surg Oncol (2009) 0.83
Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer -- 12-year single center experience. Eur J Surg Oncol (2009) 0.83
Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy in the treatment of advanced epithelial ovarian cancer. J Oncol (2012) 0.82
Three ongoing intraperitoneal chemotherapy trials in ovarian cancer. J Gynecol Oncol (2012) 0.82
Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo. Int J Hyperthermia (1995) 0.82
Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer. World J Surg Oncol (2009) 0.81
The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study. J BUON (2011) 0.80
Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. Eur J Surg Oncol (2006) 0.80
A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res (2012) 0.79
Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: experience and lessons learned. Langenbecks Arch Surg (2011) 0.78
Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer. Eur J Surg Oncol (2011) 0.78
Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer. Ann Oncol (2003) 0.78
Treatment of recurrent epithelial ovarian cancer with secondary cytoreduction and continuous intraoperative intraperitoneal hyperthermic chemoperfusion (CIIPHCP). Zentralbl Gynakol (2003) 0.77
From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer. Ann Oncol (2010) 0.77
Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol (2012) 5.06
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol (2009) 3.04
A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol (2007) 2.06
A semantic analysis of the annotations of the human genome. Bioinformatics (2005) 2.01
Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg (2010) 1.79
Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol (2008) 1.77
Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer (2008) 1.67
HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol (2010) 1.64
Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol (2009) 1.63
Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus. PLoS Genet (2011) 1.59
Pulmonary radiofrequency ablation--an international study survey. Anticancer Res (2004) 1.54
Evolution of locoregional treatment for peritoneal carcinomatosis: single-center experience of 308 procedures of cytoreductive surgery and perioperative intraperitoneal chemotherapy. Am J Surg (2010) 1.51
Recurrence after complete cryoablation of colorectal liver metastases: analysis of prognostic features. Am Surg (2006) 1.49
Secondary cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudomyxoma peritonei: a study of timing and the impact of malignant dedifferentiation. J Am Coll Surg (2010) 1.47
Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy. ANZ J Surg (2006) 1.47
Percutaneous radiofrequency ablation of pulmonary metastases from colorectal carcinoma: prognostic determinants for survival. Ann Surg Oncol (2006) 1.47
Late outcomes after drug-eluting stent implantation in "real-world" clinical practice. J Invasive Cardiol (2008) 1.46
Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. Cancer (2010) 1.46
Surgical cytoreduction and survival in appendiceal cancer peritoneal carcinomatosis: an evaluation of 46 consecutive patients. Ann Surg Oncol (2011) 1.44
Radiofrequency ablation of lung tumors: feasibility and safety. Ann Thorac Surg (2009) 1.42
Hepatectomy and lung radiofrequency ablation for hepatic and subsequent pulmonary metastases from colorectal carcinoma. J Surg Oncol (2007) 1.41
A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol (2009) 1.37
Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol (2009) 1.34
Effect of daikenchuto (TU-100) on gastrointestinal and colonic transit in humans. Am J Physiol Gastrointest Liver Physiol (2010) 1.32
Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol (2009) 1.32
Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev (2012) 1.31
Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. J Clin Invest (2014) 1.25
Towards randomized trials of cytoreductive surgery using peritonectomy and hyperthermic intraperitoneal chemotherapy for ovarian cancer peritoneal carcinomatosis. Gynecol Oncol (2009) 1.23
Hepatic resection for metastatic breast cancer: a systematic review. Eur J Cancer (2011) 1.21
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care? Ann Surg (2008) 1.20
A systematic review of radiofrequency ablation for lung tumors. Ann Surg Oncol (2008) 1.20
Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy--a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol (2007) 1.15
Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol (2009) 1.14
Diffuse malignant peritoneal mesothelioma--an update on treatment. Cancer Treat Rev (2011) 1.14
Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol (2009) 1.13
HAX1 Augments Cell Proliferation, Migration, Adhesion, and Invasion Induced by Urokinase-Type Plasminogen Activator Receptor. J Oncol (2012) 1.12
Establishing evidence for change in ovarian cancer surgery--proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis. Gynecol Oncol (2009) 1.10
Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol (2009) 1.08
Novel protein interactors of urokinase-type plasminogen activator receptor. Biochem Biophys Res Commun (2010) 1.07
Involvement of urokinase-type plasminogen activator system in cancer: an overview. Med Res Rev (2014) 1.06
Inhibitors of vascular endothelial growth factor in cancer. Cardiovasc Hematol Agents Med Chem (2008) 1.06
Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management. Can J Surg (2009) 1.06
In-line radiofrequency ablation to minimize blood loss in hepatic parenchymal transection. Am J Surg (2005) 1.05
Percutaneous imaging-guided radiofrequency ablation in patients with colorectal pulmonary metastases: 1-year follow-up. Ann Surg Oncol (2004) 1.05
A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer (2010) 1.05
Single-incision laparoscopic colectomy versus conventional multiport laparoscopic colectomy: a meta-analysis of comparative studies. Int J Colorectal Dis (2012) 1.03
Surgical metastasectomy in AJCC stage IV M1c melanoma patients with gastrointestinal and liver metastases. Ann Acad Med Singapore (2010) 1.03
The role of transversus abdominis plane blocks in women undergoing total laparoscopic hysterectomy: a retrospective review. Aust N Z J Obstet Gynaecol (2011) 1.03
Identification of SH2B2beta as an inhibitor for SH2B1- and SH2B2alpha-promoted Janus kinase-2 activation and insulin signaling. Endocrinology (2007) 1.03
Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol (2011) 1.03
A prospective longitudinal evaluation of the benefits of epicardial lead placement for cardiac resynchronization therapy. Europace (2009) 1.02
Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head Neck (2010) 1.02
Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int (2009) 1.01
Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases - a systematic review. Surg Oncol (2012) 1.01
Surgical and patient outcomes using mechanical bowel preparation before laparoscopic gynecologic surgery: a randomized controlled trial. Obstet Gynecol (2013) 1.01
Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer. Cytokine Growth Factor Rev (2012) 1.01
Exploring the role of resection of extrahepatic metastases from hepatocellular carcinoma. Surg Oncol (2011) 1.00
Preoperative investigations in the management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy: Expert consensus statement. J Surg Oncol (2008) 1.00
Development of a Bayesian Belief Network Model for personalized prognostic risk assessment in colon carcinomatosis. Am Surg (2011) 1.00
Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol (2009) 1.00
Treatment failure after percutaneous radiofrequency ablation for nonsurgical candidates with pulmonary metastases from colorectal carcinoma. Ann Surg Oncol (2007) 1.00
Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study. Ann Surg Oncol (2011) 1.00
Percutaneous radiofrequency ablation of lung tumors with expandable needle electrodes: tips from preliminary experience. AJR Am J Roentgenol (2004) 0.99
Systematic review of efficacy and outcomes of salvage liver transplantation after primary hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol (2014) 0.98
Clinicopathologic and treatment-related factors influencing recurrence and survival after hepatic resection of intrahepatic cholangiocarcinoma: a 19-year experience from an established Australian hepatobiliary unit. J Gastrointest Surg (2010) 0.98
Assessment of complement C4 gene copy number using the paralog ratio test. Hum Mutat (2010) 0.97
Solubilisation and cytotoxicity of albendazole encapsulated in cucurbit[n]uril. Org Biomol Chem (2008) 0.97
Inhibition of hepatocellular cancer by EB1089: in vitro and in vive study. Anticancer Res (2009) 0.97
Improved outcomes after aggressive surgical resection of hilar cholangiocarcinoma: a critical analysis of recurrence and survival. Am J Surg (2011) 0.96
Morbidity and mortality outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy at a single tertiary institution: towards a new perspective of this treatment. Ann Surg (2010) 0.96
Learning curve for percutaneous radiofrequency ablation of pulmonary metastases from colorectal carcinoma: a prospective study of 70 consecutive cases. Ann Surg Oncol (2006) 0.96
Summary of current therapeutic options for peritoneal metastases from colorectal cancer. J Surg Oncol (2012) 0.96
Pseudomyxoma peritonei: a need to establish evidence-based standard of care--is this the right trial? Ann Surg Oncol (2009) 0.95
Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: a review of the literature. J Med Imaging Radiat Oncol (2014) 0.95
Viewing metastatic colorectal cancer as a curable chronic disease. Am J Clin Oncol (2012) 0.94
Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery (2010) 0.94
Critical analysis of 33 patients with peritoneal carcinomatosis secondary to colorectal and appendiceal signet ring cell carcinoma. Ann Surg Oncol (2009) 0.94
Comparative analysis of perioperative intraperitoneal chemotherapy regimen in appendiceal and colorectal peritoneal carcinomatosis. Int J Clin Oncol (2012) 0.93
A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. J Cancer Res Clin Oncol (2013) 0.93
Heat sink effect on tumor ablation characteristics as observed in monopolar radiofrequency, bipolar radiofrequency, and microwave, using ex vivo calf liver model. Medicine (Baltimore) (2015) 0.93